- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Wockhardt Limited — Updates, 10-02-2026: Press Release
10-02-2026 | 03:04 pm
10-02-2026 | 03:04 pm
Wockhardt reported strong Q3 results: Revenue rose 22% to Rs. 888 Cr, while EBITDA surged 72% to Rs. 173 Cr. Biotech operations grew 96%. Its novel antibiotic, FOVISCU®, met Phase 3 endpoints, and ZAYNICH® received EMA accelerated assessment.
No comments yet. Be the first to comment!